GridAI Technologies (GRDX) Share-based Compensation (2016 - 2026)
GridAI Technologies' (GRDX) quarterly Share-based Compensation came in at $582500.0 in Q2 2026, up 21012.72% on a YoY basis from N/an in Q2 2025, and down 20.63% quarter-over-quarter from $733950.0 in Q4 2025.
Analysis
GridAI Technologies (GRDX) Share-based Compensation (2016 - 2026) Analysis & Trends
GridAI Technologies (GRDX) has reported Share-based Compensation for 11 consecutive years, with $582500.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Share-based Compensation rose 21012.72% year-over-year to $582500.0; the trailing twelve-month figure through Jun 2026 stood at $2.1 million (up 75922.11% YoY), and the FY2025 full-year result was $1.2 million, down 24.77% from the prior year.
- Share-based Compensation fell to $582500.0 in Q2 2026 per GRDX's latest filing, from $733950.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.9 million in Q1 2022 and bottomed at $2759.0 in Q2 2025.
- Historically, Share-based Compensation has averaged $673547.1 across 5 years, with a median of $757475.0 in 2024.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation sank 98.63% in 2025, then surged 21012.72% in 2026.
- Over 5 years, Share-based Compensation stood at $84346.0 in 2022, then soared by 49.53% to $126122.0 in 2023, then sank by 38.16% to $78000.0 in 2024, then soared by 840.96% to $733950.0 in 2025, then retreated by 20.63% to $582500.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $582500.0, $733950.0, and $817644.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 83.34 Mn |
| 10 | GridAI Technologies | 19.07 Mn | 19.07 Mn | -36,514.00 | 582,500.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 582,500.00 |
| Dec 31, 2025 | 733,950.00 |
| Sep 30, 2025 | 817,644.00 |
| Jun 30, 2025 | 2,759.00 |
| Mar 31, 2025 | 969,356.00 |
| Sep 30, 2024 | 78,000.00 |
| Jun 30, 2024 | 201,077.00 |
| Mar 31, 2024 | 781,000.00 |
| Dec 31, 2023 | 126,122.00 |
| Sep 30, 2023 | 600,000.00 |
| Jun 30, 2023 | 800,000.00 |
| Mar 31, 2023 | 1.10 Mn |
| Dec 31, 2022 | 84,346.00 |
| Sep 30, 2022 | 900,000.00 |
| Jun 30, 2022 | 1.10 Mn |
| Mar 31, 2022 | 1.90 Mn |
| Sep 30, 2021 | 1.10 Mn |
| Jun 30, 2021 | 4.30 Mn |
| Mar 31, 2021 | 2.47 Mn |
| Dec 31, 2020 | 152,616.00 |